

**Selected full research articles - Prof. Michel Revel (numbered as in complete listing)****A) Interferon- $\beta$** 

44. Interferon inhibits Mengo virus RNA and hemoglobin mRNA translation in cell free extracts of L cells. E. Falcoff, B. Lebleu, R. Falcoff and M. Revel. *Nature* 240, 145-148, 1972.
63. Antibodies to a cell surface component coded by chromosome 21 inhibit interferon's action. M. Revel, D. Bash and F.H. Ruddle. *Nature* 260, 139-141, 1976.
67. Specific phosphorylation in vitro of a protein associated with ribosomes of interferon-treated mouse L cells. A. Zilberstein, P. Federman, L. Shulman and M. Revel. *FEBS Letts.* 68, 119-124, 1976.
76. Isolation of two interferon-induced translational inhibitors: a protein kinase and an oligo-isoadenylate synthetase. A. Zilberstein, A. Kimchi, A. Schmidt and M. Revel. *Proc. Natl Acad. Sci USA* 75, 4734-4738, 1978.
94. Two interferon mRNAs in human fibroblasts: in vitro translation and E.coli cloning studies. J. Weissenbach, Y. Chernajovsky, M. Zeevi, L. Shulman, H. Soreq, U. Nir, D. Wallach, M. Perricaudet, P. Tiollais and M. Revel. *Proc. Natl. Acad. Sci. USA*, 77, 7152-7156, 1980.
98. Monitoring of interferon therapy by assay of (2'-5') oligo-isoadenylate synthetase in human peripheral white blood cells. A. Schattner, G. Merlin, D. Wallach, H. Rosenberg, T. Bino, T. Hahn, S. Levin and M. Revel. *J. Interferon Res.* 1, 587-593, 1981.
101. Assay of an Interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. A. Schattner, D. Wallach, G. Merlin, T. Hahn, S. Levin and M. Revel. *The Lancet* 2, 497-500, 1981.
110. Preferential effect of interferon- $\gamma$  on the synthesis of HLA antigens and their mRNAs in human cells. D. Wallach, M. Fellous and M. Revel. *Nature* 299, 833-836, 1982.
129. Effective constitutive production of human fibroblast IFN- $\beta$  by hamster cells transformed with the IFN- $\beta$ 1. gene fused to an SV40 early promoter. Y. Chernajovsky, Y. Mory, L. Chen, Z. Marks, D. Novick, M. Rubinstein and M. Revel. *DNA*, 3, 297-308, 1984.
131. Intramuscular human interferon- $\beta$  injections in treatment of condylomata acuminata (genital papilloma warts). A. Schoenfeld, S. Nitke, A. Schattner, D. Wallach, M. Crespi, T. Hahn, H. Levavi, O. Yarden, J. Shoham, T. Doerner and M. Revel. *The Lancet*, 1, 1038-1042, 1984.
142. Interferons regulate the in vitro differentiation of multilineage lympho-myeloid stem cells in Hairy Cell leukemias. R. Michalevicz and M. Revel. *Proc. Natl. Acad. Sci. USA*, 84, 2307-2311, 1987.
149. Placebo-controlled trial of topical Interferon in labial and genital Herpes. M. Glezerman, E. Lunenfeld, V. Cohen, I. Sarov, M. Movshovitz, M. Doerner, J. Shoham and M. Revel. *The Lancet*, 1, 150-152, 1988.
150. Constitutive expression of (2'-5') oligo A Synthetase confers resistance to picornavirus infection. J. Chebath, P. Benech, M. Revel and M. Vigneron. *Nature*, 330, 587-588, 1987.
157. Interferon-beta induced remission in Hairy Cell Leukemia patient resistant to interferon-alpha. R. Michalevicz, D. Aderka, B. Frisch and M. Revel. *Leukemia Res.*, 12, 845-851, 1988.
185. The human Interferon  $\alpha$ -Receptor protein confers differential responses to human Interferon- $\beta$  versus Interferon- $\alpha$  subtypes in mouse and hamster cell transfectants. C. Abramovich, J. Chebath and M. Revel. *Cytokine*, 6, 414-424, 1994.
189. Differential tyrosine phosphorylation of the IFNAR1 chain of the type I Interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta. C. Abramovich, L.M. Shulman, E. Ratovitski, S. Harroch, M. Tovey, P. Eid and M. Revel. *EMBO J.*, 13, 5871-5877, 1994.

**Selected full research articles - Prof. Michel Revel**

**A) Interferon- $\beta$  (followed)**

191. Antagonism of Interferon-beta on Interferon-gamma inhibition of signal transduction in vitro and reduction of serum IFN-gamma levels in Multiple Sclerosis patients. M. Revel, J. Chebath, M. Mangelus, S. Harroch and G.A. Moviglia. *Multiple Sclerosis*, 1, S5-S11, 1995.
193. Effects of topical Interferon- $\beta$  on recurrence rates in genital Herpes: A double-blind, placebo-controlled, randomized study. J. Ophir, S. Brenner, R. Bali, S. Kriss-Leventon, Z. Smetana and M. Revel. *J. Interferon Cytok. Res.*, 15, 625-631, 1995.
197. Immunoregulatory effects of IFN- $\beta$  and interacting cytokines on human vascular endothelial cells. Implications for Multiple Sclerosis and other autoimmune diseases. A. Miller, N. Lanis, S. Shapiro, M. Revel, S. Honigman, and A. Lahat. *J. Neuroimmunol.*, 64, 151-161, 1996.
198. A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I Interferon receptor. C. Abramovich, B. Yakobson, J. Chebath and M. Revel. *EMBO J.*, 16, 260-266, 1997.
202. Incidence of antibodies to Interferon- $\beta$  in patients treated with recombinant human Interferon- $\beta$ 1a from mammalian cells. A. Abdul-Ahad, A. Galazka, M. Revel, M. Buffoni and E.C. Borden. *Cytok. Cell. Mol. Ther.* 3, 27-32, 1997.
205. Involvement of Receptor-bound Protein Methyltransferase PRMT1 in Antiviral and Antiproliferative effects of Type 1 Interferons. L. Altschuler, J.-O. Wook, D. Gurari, J. Chebath and M. Revel. *J. Interferon Cytok. Res.*, 19, 189-195, 1998.

**B) Interferon-related studies:**

135. Structure of two forms of the interferon-induced (2'-5') oligo A synthetase of human cells based on cDNAs and gene sequences. P. Benech, Y. Mory, M. Revel and J. Chebath. *EMBO J.*, 4, 2249-2256, 1985.
137. Family of human alpha-like sequences. S.I. Feinstein, Y. Mory, Y. Chernajovsky, L. Maroteaux, U. Nir, V. Lavie and M. Revel. *Mol. Cell. Biol.*, 5, 510-517, 1985.
138. Efficient constitutive production of human IFN- $\gamma$  in Chinese hamster ovary cells. Y. Mory, L. Ben-Barak, D. Segev, B. Cohen, D. Novick, D.G. Fischer, M. Rubinstein, S. Kargman, A. Zilberstein, M. Vigneron and M. Revel. *DNA*, 5, 181-193, 1986.
155. Cloning of genomic DNA for Tumor Necrosis Factor and efficient expression in CHO cells. J.H. Korn, Y. Mory, A. Zilberstein, H. Holtman, M. Revel and D. Wallach. *Lymphokine Res.*, 7, 349-358, 1988.
156. Recombinant interferon  $\alpha$ -C for advanced Hairy cell leukemia; an Israeli multicenter study. D. Aderka, R. Michalevicz, Y. Daniel, Y. Levo, D. Douer, I. Ben-Bassat, B. Ramot, M. Shaklai, M. Prokocimer, A. Berrebi, D. Meytes, H. Rosenbaum, D. Wallach and M. Revel. *Cancer*, 61, 2207-2213, 1988.
159. DNA probes specific for *Entamoeba histolytica* possessing pathogenic and Non-pathogenic Zymodemes. L. Garfinkel, M. Giladi, M. Huber, C. Gitler, D. Mirelman, M. Revel and S. Rozenblatt. *Infection Immunity*, 57, 926-931, 1989.

**Selected full research articles - Prof. Michel Revel**

**B) Interferon-related studies (followed):**

164. Monoclonal antibodies for affinity purification of IL-6/IFN- $\beta$ 2 and for neutralization of its biological activity. D. Novick, Z. Eshhar, M. Revel and Y. Mory. *Hybridoma*, 8, 561-567, 1989.
167. Purification of soluble cytokine receptors from normal urine by ligand affinity and immuno-affinity chromatography. D. Novick, H. Engelmann, D. Wallach, O. Leitner, M. Revel and M. Rubinstein. *J. Chromatography*, 510, 331-337, 1990.
208. In vitro effects of recombinant Tumor Necrosis Factor- $\alpha$  binding protein (rTBP-1) on the hematopoiesis of HIV-infected patients. S. Gradstein, T. Hahn, Y. Barak, L. Malach, M.Revel, Z. Bentwich and Z.T. Handzel. *J. AIDS*, 26, 111-117, 2001.

**C) Interleukin-6 (IFN- $\beta$ 2)**

94. Two interferon mRNAs in human fibroblasts: in vitro translation and E.coli cloning studies. J. Weissenbach, Y. Chernajovsky, M. Zeevi, L. Shulman, H. Soreq, U. Nir, D. Wallach, M. Perricaudet, P. Tiollais and M. Revel. *Proc. Natl. Acad. Sci. USA*, 77, 7152-7156, 1980.
139. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth stimulatory cytokines. A. Zilberstein, R. Ruggieri, J.H. Korn and M. Revel. *EMBO Journal*, 5,2529-2537, 1986.
151. Growth inhibition of human Breast Carcinoma and Leukemia/Lymphoma cell lines by recombinant IFN-beta-2 (BSF-2/IL-6). L. Chen, Y. Mory, A. Zilberstein and M. Revel. *Proc. Natl. Acad. Sci. USA*, 85, 8037-8041, 1988.
153. Recombinant Interferon-beta-2 (Interleukin-6) induces myeloid differentiation. L. Chen, D. Novick, M. Rubinstein and M. Revel. *FEBS Lett.*, 239, 299-304, 1988.
161. Interferon-beta-2 (Interleukin-6) stimulates synthesis of Complement protein factor B and C3 in human skin fibroblasts. Y. Katz, M. Revel and R.C. Strunk. *Eur. J. Immunol.*, 19, 983-988, 1989.
171. Interleukin-6 induces the (2'-5') oligo A Synthetase gene in M1 cells through an effect on the Interferon-Responsive Enhancer. B. Cohen, Y. Gothelf, D. Vaiman, L. Chen, M. Revel and J. Chebath. *Cytokine*, 3, 83-91, 1991.
177. Enhancement of Interleukin-6 cytostatic effect on human breast carcinoma cells by soluble IL-6 Receptor from urine and reversion by monoclonal antibody. D. Novick, L.M. Shulman and M. Revel. *Cytokine*, 4, 6-11, 1992.
178. Antitumor effects of human rIL-6 on Acute Myeloid Leukemia in mice and in cell cultures. T. Givon, S. Slavin, N. Haran-Ghera, R. Michalevitz and M. Revel. *BLOOD*, 79, 2392-2398, 1992.
179. IL-6 gene transfection into 3LL tumor cells suppresses the malignant phenotype and confers immuno-therapeutic competence against parental metastatic cells. A. Porgador, E. Tzehoval, A. Katz, E. Vadai, M. Revel, M. Feldman and L. Eisenbach. *Cancer Res.*, 52, 3679-3686, 1992.
180. Abrogation of B16 Melanoma Metastases by Long Term Low Dose IL-6 Therapy. A. Katz, L.M. Shulman, A. Porgador, M. Revel, M. Feldman and L. Eisenbach. *J. Immunother.* 13, 98-109, 1993.
181. Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL Lung carcinomas. A. Katz, L.M. Shulman, M. Revel, M. Feldman and L. Eisenbach. *Int. J. Cancer*, 53, 812-818, 1993.

**Selected full research articles - Prof. Michel Revel**

**C) Interleukin-6 (IFN- $\beta$ 2) -followed**

182. Interleukin-6 inhibits the proliferation of B Chronic Lymphocytic Leukemia cells which is induced by Tumor Necrosis Factor- $\alpha$ , $\beta$ . D. Aderka, Y. Maor, D. Novick, H. Engelmann, Y. Kahn, Y. Levo, D. Wallach and M. Revel. *BLOOD*, 81, 2076-2084, 1993.
183. Interleukin-6 activates and regulates transcription factors of the Interferon-Regulatory-Factor (IRF) family in M1 cells. S. Harroch, Y. Gothelf, N. Watanabe, M. Revel and J. Chebath. *J. Biol. Chem.*, 268, 9092-9097, 1993.
184. Inhibition of CT-26 murine colorectal adenocarcinoma growth in the rectum of mice treated with recombinant human Interleukin-6. M. Rabau, H. Kashtan, S. Baron, J. Yossiphov, Y. Skornick, M. Revel and A. Eisenthal. *J. Immunotherapy*, 15, 257-264, 1994.
187. Induction by Interleukin-6 of Interferon Regulatory Factor-1 (IRF-1) gene expression through the palindromic Interferon Response Element pIRE and cell-type dependent control of IRF-1 binding to DNA. S. Harroch, M. Revel and J. Chebath. *EMBO J.*, 13, 1942-1949, 1994.
188. Interleukin-6 signaling via four transcription factors binding palindromic enhancers of different genes. S. Harroch, M. Revel and J. Chebath. *J. Biol. Chem.*, 269, 26191-26195, 1994.
190. Potential use of Interleukin-6 in Bone Marrow transplantation: effects of recombinant human IL-6 after syngeneic and semiallogeneic bone marrow transplantation in mice. T. Givon, M. Revel and S. Slavin. *Blood*, 83, 1690-1697, 1994.
192. Interleukin-6: Effects on tumor models in mice and on the cellular regulation of transcription factor IRF-1. M. Revel, A. Katz, L. Eisenbach, M. Feldman, N. Haran-Ghera, S. Harroch and J. Chebath. *Ann. NY Acad. Sci.*, 762, 342-356, 1995.
194. Epitope peptides from Interleukin-6 Receptor which inhibit the growth of human myeloma cells. H. Halimi, M. Eisenstein, J-W Oh, M. Revel and J. Chebath. *Eur. Cytok. Netw.*, 6, 135-143, 1995.
195. 5' upstream sequences of Myd88, an IL-6 primary response gene in M1 cells: detection of functional IRF-1 and Stat factors binding sites. *Nucl. Acid Res.*, 23, 3539-3546, 1995.
196. A soluble Interleukin-6 Receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. J-W Oh, M. Revel and J. Chebath. *Cytokine*, 8, 401-409, 1996.
199. Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. J-W Oh, A. Katz, S. Harroch, L. Eisenbach, M. Revel and J. Chebath. *Oncogene*, 14, 569-577, 1997.
202. IL-6 Receptor-IL-6 fusion proteins with enhanced IL-6-type pleiotropic activities. J. Chebath, D. Fischer, A. Kumar, J.-W. Oh, O. Kolett, T. Lapidot, M. Fisher, S. Rose-John, A. Nagler, S. Slavin and M. Revel. *Eur. Cytok. Netw.*, 8, 359-365, 1997
203. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. I. Mendel, A. Katz, N. Kozak, A. Ben-Nun and M. Revel. *Eur. J. Immunol.* 28, 1727-1737, 1998.
204. Increased sensitivity of IL-6 Deficient mice to Carbon tetrachloride Hepatotoxicity and protection by an IL-6 Receptor -IL-6 Chimera. A. Katz, J. Chebath, J. Friedman and M. Revel. *Cytok. Cell. Mol. Ther.*, 4, 221-227, 1998.
206. The soluble IL-6 Receptor/IL-6 Fusion protein enhances in vitro maintenance and proliferation of human CD34+CD38-/low cells capable of repopulating severe combined immuno-deficiency (SCID) mice. O. Kollet, R. Aviram, J. Chebath, H. ben-Hur, A. Nagler, L. Shultz, M. Revel, and T. Lapidot. *Blood*, 94, 923-931, 1999.

**Selected full research articles - Prof. Michel Revel**

**C) Interleukin-6 (IFN-β2) -followed**

207. Induction of myelin gene expression in Schwann cell cultures by an interleukin-6 receptor interleukin-6 chimera. S. Haggiag, J. Chebath and M. Revel. FEBS Letters 457, 200-204, 1999.
209. Stimulation of myelin gene expression in vitro and of sciatic nerve remyelination by Interleukin-6 receptor – Interleukin-6 chimera. S. Haggiag, P.-L. Zhang, G. Slutsky, V. Shinder, A. Kumar, J. Chebath and M. Revel., J. Neuroscience Res., 64, 564-574, 2001.
210. Pax-3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by Interleukin-6 receptor signalling. A. Kumar Kamaraju , C. Bertolotto, J. Chebath and M. Revel. J. Biol. Chem. 277, 15132-15141, 2002.
211. Activation of Myelin genes during transdifferentiation from melanoma to glial cell phenotype. S. G. Slutsky, A. Kumar Kamaraju, A. Levy, J. Chebath and M. Revel. J. Biol. Chem. 278 , 8960-8968, 2003.
212. HGF, SDF-1 and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. O. Kollet, [...], M. Revel, D.A. Shafritz and T. Lapidot. J. Clin. Invest. 112, 160-169, 2003.
213. C/EBP-δ induction by gp130 signaling: role in transition to myelin gene expression phenotype in a melanoma cell line model. A. Kumar Kamaraju, S. Adjalley, P.L. Zhang, J. Chebath and M. Revel. J. Biol. Chem. 279, 3852-3861, 2004.
214. Enhancement of oligodendrocyte differentiation from murine embryonic stem (ES) cells by an activator of gp130 signaling. P.L. Zhang, J. Chebath, P. Lonai and M. Revel. STEM CELLS, 22, 344-354, 2004.
215. Increased myelination capacity of embryonic stem cell derived oligodendrocyte precursors after treatment by interleukin-6/soluble interleukin-6 receptor fusion protein. P.L. Zhang, M. Izrael, E. Ainbinder, L. Ben-Simchon, J. Chebath and M. Revel. Mol.Cell.Neurosci., 2005.

**Selected Books and Reviews - Prof. Michel Revel**

- Book: Atlas de Biologie Moleculaire, M. Herzberg and M. Revel. Editions Hermann, Paris, 1972
- Book: Clinical Aspects of Interferons. Michel Revel, Editor. Kluwer Academic Publ., Boston, 1988..
- Book: IL-6 Physiopathology and clinical potentials. M. Revel, editor. Serono Symposia, Vol 88, Raven Press, New York, 1992.
- Review Chapter: Interferon-activated genes. M. Revel and J. Chebath. Trends in Biochemical Sciences, 11, 166-170, 1986.
- Review Chapter: Host defense against infections and inflammations: Role of the multifunctional IL-6/IFN-beta-2 cytokine. M. Revel. Experientia, 45, 549-557, 1989.
- Review Chapter: Antitumor potential of Interleukin-6. Interferon and Cytokines, 19, 5-8, 1991.
- Review Chapter: Growth regulatory functions of IL-6 and antitumor effects. M. Revel. in Forum in Immunology: Forum on IL-6. Research in Immunol. 143, 769-773, 1992.
- Review Chapter: The 2'-5' A System: 2'-5' A Synthetases, isospecies and functions. J. Chebath and M. Revel. in Interferon, principles and medical applications. S. Baron et al (eds), University of Texas Medical Branch at Galveston, TX, pp 225-236, 1992..
- Review Chapter: Treatment of Cervical Intraepithelial Neoplasia and Invasive Squamous Cell Carcinoma by Interferon. J. Bornstein, Y. Ben-David, J. Atad, B. Pascal and H. Abramovici. Obstetrical and Gynecological Survey, 48, 251-260, 1993.
- Review Chapter: Glycosylated Interferon-beta in Multiple Sclerosis. M. Revel and P. Kalinka In: Frontiers in Multiple Sclerosis. Clinical Research and Therapy. O. Ambramsky, H. Ovardia (eds). Martin Dunitz Publ., pp. 243-254, 1997.
- Review Chapter: Interferon-beta: Structure, Differential actions and Medical applications. M. Revel. In: Growth Factors and Cytokines in Health and Disease. D. LeRoith, C. Bondy (eds), JAI Press Inc. Volume 2B, pp 433-520, 1997.
- Review Chapter: IFN-beta in the treatment of Multiple Sclerosis. M. Revel. Pharmacology and Therapeutics. Vol. 100, pp. 49-62, 2003.

**Selected BIOETHICS articles: Michel Revel**

- Report on Genetic Counselling**, Proc. UNESCO International Bioethics Committee, 1996
- An outright, upfront condemnation of cloning research is premature**. *The Scientist*, 12, 38, 1998
- L'éthique ne doit pas interdire d'emblée**. *La Croix*, March 1999.
- Ongoing research on Mammalian cloning and Embryo Stem Cell technologies: Bioethics of their potential Medical Applications**. *Israel Medical Assoc. Journal* 2, suppl: 8-14, 2000
- Report on Human Embryo Stem Cell Research**. UNESCO International Bioethics Committee, 2001.
- Report on Human Embryo Stem Cell Research in Israel**. Bioethics Committee of the Israel Academy of Science and Humanities (as chair), 2001.
- Ashes from a stolen flame (on Prometheus)**. M. Revel. *Haaretz*, 4 May 2001.
- Report on Population-based Large-Scale Collections of DNA Samples and Databases of Genetic Information**. Bioethics Committee of the Israel Academy of Science and Humanities (as chair), 2002.
- Pour un clonage reproductif humain maîtrisé**. M. Revel. *Le Monde*, 4 Janvier 2003.
- Demain les clones**. M. Revel. *Liberation*, 27 Fevrier 2003.
- Human Reproductive Cloning, Embryo Stem Cells and Germline Gene Intervention: An Israeli Perspective**. M. Revel. *Medicine and Law*, 22, 701-732, 2003.
- Science, Ethics and Arms of Mass Destructions** (Hebrew). M. Revel. *Academia* 12, 4-7, 2003.
- The Ethical Issues raised by Behavioral Genetics in Humans**. M. Revel. *Proceedings of the International Bioethics Committee, Unesco, 9<sup>th</sup> session, Vol II, 81-94, Unesco Publications 2003.*
- Are Genes Our Destiny?** - Implications and Ethical limitations of Genetic Determinism in Medicine and Behavioural Sciences. M. Revel. In: *The Embryo: Scientific Discovery and Medical Ethics*, S. Blazer, E.Z. Zimmer eds., Karger Pub., Basel, 2005, pp143-165.
- Ethical issues of Human Embryo cloning technologies for Stem Cell research**. M. Revel. In: *The Embryo: Scientific Discovery and Medical Ethics*, S. Blazer, E.Z. Zimmer eds., Karger Pub., Basel, 2005, pp107-119.
- UNESCO Universal Declaration on Bioethics and Human Rights: Why there is a need to take Cultural Diversity into account**. M. Revel, *Proceedings of the International Bioethics Committee, Unesco, 12<sup>th</sup> session, Unesco Publications, 2005.*
- Research on Human Embryonic Stem cells and cloning for Stem Cells**. M. Revel. In: *Common Values in the European Research Area*. ALLEA (All European Academies) Publications, 2006.